Robin Christensen1,2, Lara J Maxwell3,4, Peter Jüni3,4, David Tovey3,4, Paula R Williamson3,4, Maarten Boers3,4, Niti Goel3,4, Rachelle Buchbinder3,4, Lyn March3,4, Caroline B Terwee3,4, Jasvinder A Singh3,4, Peter Tugwell3,4. 1. From the Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; Bispebjerg and Frederiksberg, Denmark; Institute of Population Health, and Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Institute of Social and Preventive Medicine and Clinical Trials Unit Bern, Department of Clinical Research, University of Bern, Bern, Switzerland; Cochrane Collaboration, London; Department of Biostatistics, University of Liverpool, Liverpool, UK; departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; Quintiles Inc.; Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, and Monash Department of Clinical Epidemiology, Cabrini Health, Melbourne; Northern Clinical School, Institute of Bone and Joint Research, University of Sydney, Department of Rheumatology, Sydney, Australia; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands; Birmingham Veterans Affairs (VA) Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA. robin.christensen@regionh.dk. 2. R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; L.J. Maxwell, Institute of Population Health, University of Ottawa; P. Jüni, MD, Institute of Social and Preventive Medicine and Clinical Trials Unit Bern, Department of Clinical Research, University of Bern; D. Tovey, Cochrane Collaboration; P.R. Williamson, Department of Biostatistics, University of Liverpool; M. Boers, MD, PhD, Departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center; N. Goel, Quintiles Inc., Division of Rheumatology, Department of Medicine, Duke University School of Medicine, and Patient Research Partner; R.S. Buchbinder, MBBS (Hons), MSc, PhD, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, and Monash Department of Clinical Epidemiology, Cabrini Health; L. March, MD, PhD, Northern Clinical School, Institute of Bone and Joint Research, University of Sydney, Department of Rheumatology; C.B. Terwee, Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VU University Medical Center; J.A. Singh, MBBS, MPH, Birmingham VA Medical Center and University of Alabama at Birmingham; P. Tugwell, MD, MSc, The Department of Medicine, University of Ottawa. robin.christensen@regionh.dk. 3. From the Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; Bispebjerg and Frederiksberg, Denmark; Institute of Population Health, and Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Institute of Social and Preventive Medicine and Clinical Trials Unit Bern, Department of Clinical Research, University of Bern, Bern, Switzerland; Cochrane Collaboration, London; Department of Biostatistics, University of Liverpool, Liverpool, UK; departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center, Amsterdam, The Netherlands; Quintiles Inc.; Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, and Monash Department of Clinical Epidemiology, Cabrini Health, Melbourne; Northern Clinical School, Institute of Bone and Joint Research, University of Sydney, Department of Rheumatology, Sydney, Australia; Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands; Birmingham Veterans Affairs (VA) Medical Center and University of Alabama at Birmingham, Birmingham, Alabama, USA. 4. R. Christensen, BSc, MSc, PhD, Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital; L.J. Maxwell, Institute of Population Health, University of Ottawa; P. Jüni, MD, Institute of Social and Preventive Medicine and Clinical Trials Unit Bern, Department of Clinical Research, University of Bern; D. Tovey, Cochrane Collaboration; P.R. Williamson, Department of Biostatistics, University of Liverpool; M. Boers, MD, PhD, Departments of Epidemiology and Biostatistics, and Rheumatology, VU University Medical Center; N. Goel, Quintiles Inc., Division of Rheumatology, Department of Medicine, Duke University School of Medicine, and Patient Research Partner; R.S. Buchbinder, MBBS (Hons), MSc, PhD, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, and Monash Department of Clinical Epidemiology, Cabrini Health; L. March, MD, PhD, Northern Clinical School, Institute of Bone and Joint Research, University of Sydney, Department of Rheumatology; C.B. Terwee, Department of Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VU University Medical Center; J.A. Singh, MBBS, MPH, Birmingham VA Medical Center and University of Alabama at Birmingham; P. Tugwell, MD, MSc, The Department of Medicine, University of Ottawa.
Abstract
OBJECTIVE: Although protocol registration for systematic reviews is still not mandatory, reviewers should be strongly encouraged to register the protocol to identify the methodological approach, including all outcomes of interest. This will minimize the likelihood of biased decisions in reviews, such as selective outcome reporting. A group of international experts convened to address issues regarding the need to develop hierarchical lists of outcome measurement instruments for a particular outcome for metaanalyses. METHODS: Multiple outcome measurement instruments exist to measure the same outcome. Metaanalysis of knee osteoarthritis (OA) trials, and the assessment of pain as an outcome, was used as an exemplar to assess how Outcome Measures in Rheumatology (OMERACT), the Cochrane Collaboration, and other international initiatives might contribute in this area. The meeting began with formal presentations of background topics, empirical evidence from the literature, and a brief introduction to 2 existing hierarchical lists of pain outcome measurement instruments recommended for metaanalyses of knee OA trials. RESULTS: After discussions, most participants agreed that there is a need to develop a methodology for generation of hierarchical lists of outcome measurement instruments to guide metaanalyses. Tools that could be used to steer development of such a prioritized list are the COSMIN checklist (COnsensus-based Standards for the selection of health status Measurement Instruments) and the OMERACT Filter 2.0. CONCLUSION: We list meta-epidemiological research agenda items that address the frequency of reported outcomes in trials, as well as methodologies to assess the best measurement properties (i.e., truth, discrimination, and feasibility).
OBJECTIVE: Although protocol registration for systematic reviews is still not mandatory, reviewers should be strongly encouraged to register the protocol to identify the methodological approach, including all outcomes of interest. This will minimize the likelihood of biased decisions in reviews, such as selective outcome reporting. A group of international experts convened to address issues regarding the need to develop hierarchical lists of outcome measurement instruments for a particular outcome for metaanalyses. METHODS: Multiple outcome measurement instruments exist to measure the same outcome. Metaanalysis of knee osteoarthritis (OA) trials, and the assessment of pain as an outcome, was used as an exemplar to assess how Outcome Measures in Rheumatology (OMERACT), the Cochrane Collaboration, and other international initiatives might contribute in this area. The meeting began with formal presentations of background topics, empirical evidence from the literature, and a brief introduction to 2 existing hierarchical lists of pain outcome measurement instruments recommended for metaanalyses of knee OA trials. RESULTS: After discussions, most participants agreed that there is a need to develop a methodology for generation of hierarchical lists of outcome measurement instruments to guide metaanalyses. Tools that could be used to steer development of such a prioritized list are the COSMIN checklist (COnsensus-based Standards for the selection of health status Measurement Instruments) and the OMERACT Filter 2.0. CONCLUSION: We list meta-epidemiological research agenda items that address the frequency of reported outcomes in trials, as well as methodologies to assess the best measurement properties (i.e., truth, discrimination, and feasibility).
Authors: Anthony M Rossi; Joseph Sobanko; Naomi Lawrence; Jeremy Bordeaux; Todd Cartee; Eric S Armbrecht; Anit Behera; Christian L Baum; Murad Alam; Ian A Maher Journal: Dermatol Surg Date: 2019-07 Impact factor: 3.398
Authors: Augustine C Lee; Jeffrey B Driban; Lori Lyn Price; William F Harvey; Angie Mae Rodday; Chenchen Wang Journal: J Pain Date: 2017-05-10 Impact factor: 5.820
Authors: Todd V Cartee; Murad Alam; Eric S Armbrecht; Anit Behera; Naomi Lawrence; Jeremy S Bordeaux; Christian L Baum; Anthony Rossi; Ian A Maher Journal: Dermatol Surg Date: 2019-02 Impact factor: 3.398
Authors: Matthew J Parkes; Michael J Callaghan; Terence W O'Neill; Laura M Forsythe; Mark Lunt; David T Felson Journal: Arthritis Care Res (Hoboken) Date: 2016-07-28 Impact factor: 4.794